Iproteos
Biotechnology company determined to improve human health by creating therapeutics for unmet medical needs in the central nervous system space.
- dt and ls
- biotechnology
- horizon europe
- biotech and pharma
- woman founder
- spinout
- eit ecosystem
- neurology
- drug development
- eit health
- eit supernovas
- innovation management
- chemistry
- european health catapult (eit health)
- investor network (eit health)
- investor network 2018 (eit health)
- european health catapult 2019 (eit health)
- epilepsy
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (65 %) | 262 % | (90 %) | (60 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 66 % | (415 %) | (51 %) | (682 %) | (3229 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (32 %) | (645 %) | (136 %) | (2412 %) | (13064 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Iproteos is a biotechnology company co-founded by researchers Dr. Teresa Tarragó and Ernest Giralt as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona (UB). The company focuses on the development of third-generation drugs for diseases of the central nervous system, such as schizophrenia and epilepsy, as well as for cancer.
The company's core technology, the IPROTech platform, enables the rapid and efficient discovery of peptidomimetic therapeutics. These are non-natural peptides that are intermediate in size between small molecules and biologics, and are designed to be cell-permeable and highly stable. Iproteos leverages this platform to create therapeutics for diseases that are currently difficult to target by modulating protein-ligand and protein-protein interactions.
Iproteos' business model is centered on the research and development of new therapeutic strategies. The company serves the pharmaceutical and biotechnology industries by developing novel drug candidates for unmet medical needs. Its primary market is the drug development sector, with a specific focus on CNS disorders and oncology.
Keywords: biotechnology, peptidomimetic therapeutics, central nervous system, oncology, drug development, protein-ligand interactions, protein-protein interactions, IPROTech platform, IRB Barcelona, University of Barcelona